Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitalization | 6 | 2025 | 1393 | 1.330 |
Why?
|
| Anti-Bacterial Agents | 14 | 2024 | 822 | 1.310 |
Why?
|
| Klebsiella Infections | 2 | 2021 | 22 | 1.260 |
Why?
|
| Klebsiella pneumoniae | 2 | 2021 | 30 | 1.250 |
Why?
|
| Bacteremia | 3 | 2021 | 95 | 1.250 |
Why?
|
| beta-Lactamases | 5 | 2021 | 14 | 1.160 |
Why?
|
| Internal Medicine | 4 | 2024 | 163 | 1.050 |
Why?
|
| Escherichia coli Infections | 2 | 2018 | 90 | 1.040 |
Why?
|
| Escherichia coli | 3 | 2018 | 727 | 0.910 |
Why?
|
| Chloramphenicol | 1 | 2024 | 6 | 0.860 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 1145 | 0.850 |
Why?
|
| Risk Adjustment | 2 | 2024 | 94 | 0.840 |
Why?
|
| Patient Admission | 1 | 2025 | 199 | 0.800 |
Why?
|
| Israel | 7 | 2024 | 26 | 0.780 |
Why?
|
| Pneumonia | 1 | 2025 | 293 | 0.730 |
Why?
|
| Crowding | 1 | 2021 | 34 | 0.700 |
Why?
|
| Colistin | 1 | 2021 | 7 | 0.690 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 6 | 0.590 |
Why?
|
| Inpatients | 1 | 2021 | 311 | 0.550 |
Why?
|
| Cattle Diseases | 1 | 2017 | 12 | 0.520 |
Why?
|
| Career Choice | 1 | 2018 | 133 | 0.500 |
Why?
|
| Pandemics | 2 | 2021 | 676 | 0.490 |
Why?
|
| Diabetic Foot | 1 | 2016 | 12 | 0.480 |
Why?
|
| Carbapenems | 3 | 2020 | 8 | 0.460 |
Why?
|
| Staphylococcal Infections | 3 | 2016 | 136 | 0.420 |
Why?
|
| Daptomycin | 3 | 2009 | 9 | 0.410 |
Why?
|
| Tertiary Care Centers | 2 | 2024 | 113 | 0.410 |
Why?
|
| Length of Stay | 3 | 2024 | 831 | 0.400 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2020 | 11 | 0.400 |
Why?
|
| Enterobacteriaceae | 3 | 2020 | 18 | 0.400 |
Why?
|
| Aged | 9 | 2025 | 14946 | 0.380 |
Why?
|
| Humans | 30 | 2025 | 65528 | 0.370 |
Why?
|
| Hospital Mortality | 3 | 2025 | 879 | 0.350 |
Why?
|
| Staphylococcus aureus | 3 | 2016 | 184 | 0.340 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 5611 | 0.330 |
Why?
|
| Retrospective Studies | 9 | 2024 | 6882 | 0.330 |
Why?
|
| Internship and Residency | 1 | 2018 | 815 | 0.320 |
Why?
|
| Shigella Vaccines | 3 | 2005 | 3 | 0.320 |
Why?
|
| Male | 15 | 2025 | 31073 | 0.310 |
Why?
|
| Female | 16 | 2025 | 34125 | 0.300 |
Why?
|
| Middle Aged | 11 | 2025 | 18266 | 0.290 |
Why?
|
| Cross Infection | 2 | 2020 | 168 | 0.270 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 23 | 0.270 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5819 | 0.270 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2020 | 60 | 0.260 |
Why?
|
| Community-Acquired Infections | 1 | 2007 | 94 | 0.250 |
Why?
|
| Sepsis | 2 | 2021 | 293 | 0.250 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 214 | 0.250 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2021 | 96 | 0.220 |
Why?
|
| Intensive Care Units | 2 | 2025 | 423 | 0.210 |
Why?
|
| Shigella flexneri | 1 | 2004 | 19 | 0.210 |
Why?
|
| Demography | 1 | 2024 | 180 | 0.210 |
Why?
|
| Enterotoxins | 1 | 2003 | 21 | 0.190 |
Why?
|
| Escherichia coli Vaccines | 1 | 2003 | 11 | 0.190 |
Why?
|
| Adult | 13 | 2024 | 17418 | 0.190 |
Why?
|
| Bacterial Toxins | 1 | 2003 | 63 | 0.190 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 1114 | 0.180 |
Why?
|
| Antigens, Bacterial | 1 | 2003 | 201 | 0.180 |
Why?
|
| Multilocus Sequence Typing | 1 | 2021 | 5 | 0.170 |
Why?
|
| Comorbidity | 1 | 2024 | 1125 | 0.170 |
Why?
|
| Enterobacter | 1 | 2020 | 5 | 0.170 |
Why?
|
| Sinorhizobium meliloti | 1 | 2020 | 4 | 0.170 |
Why?
|
| Bacteriuria | 1 | 2020 | 16 | 0.160 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2020 | 25 | 0.160 |
Why?
|
| Plant Roots | 1 | 2020 | 62 | 0.160 |
Why?
|
| Plasmids | 1 | 2021 | 297 | 0.160 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 278 | 0.160 |
Why?
|
| Bacterial Proteins | 3 | 2021 | 784 | 0.160 |
Why?
|
| Shock, Septic | 1 | 2020 | 87 | 0.150 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 153 | 0.150 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1157 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2020 | 155 | 0.150 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 272 | 0.140 |
Why?
|
| Virulence | 2 | 2017 | 199 | 0.140 |
Why?
|
| Risk Assessment | 1 | 2025 | 2101 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 109 | 0.140 |
Why?
|
| Patient Discharge | 1 | 2021 | 522 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2021 | 384 | 0.130 |
Why?
|
| Bacterial Shedding | 1 | 2017 | 1 | 0.130 |
Why?
|
| Schools, Medical | 1 | 2018 | 151 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2021 | 1020 | 0.130 |
Why?
|
| beta-Lactam Resistance | 1 | 2016 | 4 | 0.120 |
Why?
|
| Virulence Factors | 1 | 2017 | 85 | 0.120 |
Why?
|
| Acinetobacter baumannii | 1 | 2016 | 5 | 0.120 |
Why?
|
| Acinetobacter Infections | 1 | 2016 | 7 | 0.120 |
Why?
|
| Environment | 1 | 2017 | 126 | 0.120 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cattle | 1 | 2017 | 321 | 0.120 |
Why?
|
| Family Practice | 1 | 2018 | 216 | 0.120 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2016 | 17 | 0.120 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 37 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 282 | 0.110 |
Why?
|
| Shigella sonnei | 2 | 2005 | 3 | 0.110 |
Why?
|
| Antibodies, Bacterial | 3 | 2004 | 183 | 0.100 |
Why?
|
| Hospitals | 3 | 2021 | 391 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 194 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 716 | 0.100 |
Why?
|
| Mutation | 1 | 2021 | 2679 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2783 | 0.080 |
Why?
|
| Vaccines, Attenuated | 3 | 2005 | 36 | 0.080 |
Why?
|
| Endocarditis | 1 | 2009 | 29 | 0.070 |
Why?
|
| Immunoglobulin A | 3 | 2005 | 103 | 0.070 |
Why?
|
| Child | 1 | 2018 | 4678 | 0.070 |
Why?
|
| Administration, Oral | 3 | 2005 | 376 | 0.070 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2007 | 13 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 208 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 2635 | 0.060 |
Why?
|
| Immunoglobulin G | 2 | 2005 | 469 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2007 | 877 | 0.050 |
Why?
|
| Adolescent | 3 | 2004 | 6383 | 0.050 |
Why?
|
| Phenotype | 1 | 2007 | 1242 | 0.050 |
Why?
|
| Feces | 1 | 2004 | 117 | 0.050 |
Why?
|
| Capsules | 1 | 2003 | 33 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2003 | 81 | 0.050 |
Why?
|
| Immunization | 1 | 2003 | 137 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2003 | 178 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 116 | 0.040 |
Why?
|
| Ascitic Fluid | 1 | 2020 | 12 | 0.040 |
Why?
|
| Urinalysis | 1 | 2020 | 37 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2020 | 31 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2024 | 446 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 59 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 293 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 99 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5442 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2020 | 43 | 0.040 |
Why?
|
| Device Removal | 1 | 2020 | 66 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 134 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 177 | 0.040 |
Why?
|
| Animals | 1 | 2017 | 21529 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2020 | 222 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1217 | 0.030 |
Why?
|
| Cefazolin | 1 | 2016 | 11 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1410 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2004 | 1560 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 106 | 0.030 |
Why?
|
| Inappropriate Prescribing | 1 | 2016 | 68 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2016 | 121 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 427 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 937 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2432 | 0.020 |
Why?
|
| Lipopolysaccharides | 2 | 2005 | 627 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 178 | 0.020 |
Why?
|
| Outpatients | 1 | 2009 | 142 | 0.020 |
Why?
|
| United States | 1 | 2020 | 8130 | 0.020 |
Why?
|
| Antibody-Producing Cells | 1 | 2005 | 12 | 0.010 |
Why?
|
| Dysentery, Bacillary | 1 | 2005 | 14 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 316 | 0.010 |
Why?
|
| Lactoferrin | 1 | 2002 | 37 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 749 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 579 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 4836 | 0.010 |
Why?
|